BIOM's Story

Biomira, Canadian Biotech company, will present updated survival rates on its lead candidate BLP25. Please remember that BLP25 has only gotten through Phase 2B trials only. Their partner is Merck Kgaa (Germany) not Merck & Co. We already know BLP25 has had impressive results on the last update given in early Dec 2004, that was the reason for the super spike you see on the charts. They will release updated survival rates, and we will know if Medium Survival Rates (MST) has been met or not. The last update indicated that MST has not been met. Which is a good thing.

Here's the Press Release Feb 22nd, 2005 Headline
American Society of Clinical Oncology (ASCO) Accepts Biomira's BLP25 Liposome Vaccine Phase IIb Non-Small Cell Lung Cancer Trial Results for Two Poster Presentations at 2005 Meeting

The meeting will take place in Orlando, Florida, May 13-17, 2005.


The ASCO Annual Meeting is the premier educational and scientific event for oncology professionals. The 2005 meeting is expected to attract more than 28,000 attendees from all over the world.


L-BLP25 is a synthetic MUC1 peptide vaccine. L-BLP25 incorporates a 25-amino acid sequence of the MUC1 cancer mucin, encapsulated in a liposomal delivery system. The liposome enhances recognition of the cancer antigen by the immune system and facilitates better delivery. L-BLP25 is designed to induce an immune response to cancer cells.


If you check up Dendreon (DNDN) they will also be presenting at ASCO had an impressive day today.

The professionals that attend ASCO have already received abstracts for the companies' presenting, look for more volatity in the Biotech sector and for possible news leak.


BoomTime